<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48642">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01953328</url>
  </required_header>
  <id_info>
    <org_study_id>20120122</org_study_id>
    <nct_id>NCT01953328</nct_id>
  </id_info>
  <brief_title>Study of LDL-Cholesterol Reduction Using Evolocumab (AMG145) in Japanese Patients With Advanced Cardiovascular Risk</brief_title>
  <acronym>AMG145</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis is that both dosing regimens of evolocumab (AMG 145) SC will be well
      tolerated and will result in greater reduction of LDL-C, compared with placebo, when used in
      combination with statin therapy in subjects with high cardiovascular risk and with
      hyperlipidemia or mixed dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in low density lipoprotein-cholesterol</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline in low density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in low density lipoprotein-cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in low density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in non-high density lipoprotein-cholesterol</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in non-high density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non-high density lipoprotein-cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in non-high density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in apolipoprotein B</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in apolipoprotein B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in apolipoprotein B</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in apolipoprotein B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in total cholesterol</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in the total cholesterol/high density lipoprotein-cholesterol ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in apolipoprotein B/apolipoprotein A1 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Low density lipoprotein-cholesterol response (low density lipoprotein-cholesterol &lt; 70 mg/dL [1.8 mmol/L])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in lipoprotein (a)</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in lipoprotein (a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in lipoprotein (a)</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in lipoprotein (a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in triglycerides</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in triglycerides</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in high density lipoprotein-cholesterol</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in high density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in high density lipoprotein-cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in high density lipoprotein-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean percent change from baseline in very low-density lipoprotein cholesterol</measure>
    <time_frame>10 and 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean percent change from baseline in very low-density lipoprotein cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in very low-density lipoprotein cholesterol</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in very low-density lipoprotein cholesterol</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events</condition>
  <arm_group>
    <arm_group_label>Statin (Arm A and Arm B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are randomized to a low and high dose of a statin; then subjects are randomized to one of the following: Arm 1, Arm 2, Arm 3 or Arm 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose 1 - placebo every two weeks - subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 - evolocumab (AMG 145) study drug every two weeks - subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose 3 - placebo once a month - subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 - evolocumab (AMG 145) study drug once a month - subcutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Patients are randomized to low and high dose of a statin; then subjects are randomized to one of the following:</description>
    <arm_group_label>Statin (Arm A and Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All patients at screening will participate in the placebo run-in dosing subcutaneous. Patients will receive placebo every 2 weeks or monthly subcutaneous.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Study Drug</intervention_name>
    <description>Patients will receive evolocumab (AMG145) every 2 weeks or monthly subcutaneous.</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:  Male or female, Japanese adult,  20-85 years of age; Subjects on
        stable dose of statin for greater than equal to 4 weeks; Fasting LDL-C greater than equal
        to 100 mg/dL; Fasting triglycerides less than equal to 400 mg/dL; Subject is at high risk
        for cardiovascular events. Exclusion Criteria:  NYHA III or IV - heart failure;
        Uncontrolled cardiac arrhythmia; Uncontrolled hypertension; Type 1 diabetes, poorly
        controlled type 2 diabetes; Uncontrolled hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akita-shi</city>
        <state>Akita</state>
        <zip>010-1423</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Noda-shi</city>
        <state>Chiba</state>
        <zip>278-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>810-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>810-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>819-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakyusyu-shi</city>
        <state>Fukuoka</state>
        <zip>807-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-8041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-8832</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-8862</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-0209</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koriyama-shi</city>
        <state>Fukushima</state>
        <zip>963-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takasaki-shi</city>
        <state>Gunma</state>
        <zip>370-3524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>003-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>003-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsuchiura-shi</city>
        <state>Ibaraki</state>
        <zip>300-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanamaki-shi</city>
        <state>Iwate</state>
        <zip>025-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <zip>760-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <zip>760-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>615-8125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>983-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>983-0835</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>989-3122</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomigusuku-shi</city>
        <state>Okinawa</state>
        <zip>901-0243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urasoe-shi</city>
        <state>Okinawa</state>
        <zip>901-2132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ibaraki-shi</city>
        <state>Osaka</state>
        <zip>567-0876</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <zip>560-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koshigaya-shi</city>
        <state>Saitama</state>
        <zip>343-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumagaya-shi</city>
        <state>Saitama</state>
        <zip>360-0816</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Niiza-shi</city>
        <state>Saitama</state>
        <zip>352-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arakawa-ku</city>
        <state>Tokyo</state>
        <zip>116-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chofu-shi</city>
        <state>Tokyo</state>
        <zip>182-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>133-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <zip>124-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-7390</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>144-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>155-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-6003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>140-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese, high cholesterol, LDL-C, High Cardiovascular Risk</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
